Introgen Therapeutics, Inc. Cuts 29% of Jobs as it Moves to Market Cancer Therapy
Introgen Therapeutics Inc. is reducing its development staff to focus on regulatory review and commercial activities. The pharmaceutical company that is working on cancer therapies plans to cut 20 of its 70 employees. The jobs eliminated are mainly associated with Advexin development and regulatory submission programs that have been recently completed.